EMPOWERING MYELOMA ADVOCACY ACROSS EUROPE
Skip to content
Search:
About us
Contact us
Superior MPE
Myeloma Patients Europe
Myeloma and AL Amyloidosis
Multiple Myeloma
About AL amyloidosis
What we do
Member and patient community programmes
MPE Masterclass
Scholarship programme
Myeloma CABs
MPE Myeloma and AL amyloidosis Community Taskforce
Advocate Development Programme
Reasonable Agreements between Patient Advocates and Pharmaceutical Companies (RAPP)
COVID-19
Research
Patient Evidence
Horizon Europe
IMI
Access
Access to myeloma treatment
CEE workgroup on Access
Myeloma Trial Navigator
Educational resources
Educational clips
Webinars
Q&As
Toolkits
Factsheets
Conference reports
Patient guides
European Myeloma Day
News
Privacy Policy
Cookies Policy
Facebook page opens in new window
Twitter page opens in new window
YouTube page opens in new window
Linkedin page opens in new window
EMPOWERING MYELOMA ADVOCACY ACROSS EUROPE
About MPE
Our members
Our board and staff
Medical Advisory Commitee
Our funding
Get involved in MPE activities
Become a MPE member
Contact us
Myeloma and AL Amyloidosis
About myeloma
What is myeloma?
What causes myeloma?
Coping with a myeloma diagnosis
Early diagnosis and smoldering myeloma
Diagnostic tests
Treatment of myeloma
Myeloma symptoms and treatment side-effects
Caring for yourself
Dealing with the psycho-social aspects of the disease
Managing myeloma and work, finance and advance decisions
Myeloma landscape and future directions
Clinical trials
Finding out about myeloma clinical trials
About AL amyloidosis
Symptoms of AL amyloidosis
AL amyloidosis diagnosis
AL amyloidosis treatment
Living with AL amyloidosis
AL amyloidosis: caring for yourself
AL amyloidosis treatment side effects
Socio-economical impact
Advance decisions
Novel treatment options in AL amyloidosis
AL amyloidosis clinical trials
What we do
Member and patient community programmes
MPE Masterclass
Scholarship programme
Myeloma CABs
MPE Myeloma and AL amyloidosis Community Taskforce
Advocate Development Programme
COVID-19
Reasonable Agreements between Patient Advocates and Pharmaceutical Companies (RAPP)
Research
Patient Evidence
Horizon Europe
MMPredict
CARAMBA
IMI
Harmony
Sisaqol
Access
Access to myeloma treatment
CEE workgroup on Access
Myeloma and AL Amyloidosis Trial Navigator
Educational resources
Educational clips
Webinars
Q&As
Toolkits
Factsheets
Conference reports
Patient guides
News
European Myeloma Day
European Myeloma Day | Learn
European Myeloma Day | Share
European Myeloma Day | Change
Myeloma infographics
AL amyloidosis infographics
Videos
PATRICIA MATAMOROS
Communications
PATRICIA MATAMOROS
By
admin2
December 17, 2021
ANA VALLEJO
Communications
ANA VALLEJO
By
admin2
December 17, 2021
VALENTINA CHRISTODOULIDOU
Finance & Operations
VALENTINA CHRISTODOULIDOU
By
admin2
December 17, 2021
INGRID JENISCH
Finance & Operations
INGRID JENISCH
By
admin2
December 17, 2021
LILI GUNDELACH
Medical Education & Scientific Engagement
LILI GUNDELACH
By
admin2
December 17, 2021
SOLÈNE CLAVREUL
Medical Education & Scientific Engagement
SOLÈNE CLAVREUL
By
admin2
December 17, 2021
SILENE TEN SELDAM
Evidence Generation Unit (EGU)
SILENE TEN SELDAM
By
admin2
December 17, 2021
JAYNE GALINSKY
Evidence Generation Unit (EGU)
JAYNE GALINSKY
By
admin2
December 17, 2021
LINDA CHRISTOPHER
Capacity Building & Advocacy
LINDA CHRISTOPHER
By
admin2
December 17, 2021
KATIE JOYNER
Capacity Building & Advocacy
KATIE JOYNER
By
admin2
December 17, 2021
Go to Top
I am a
*
Patient
Patient advocate
Caregiver
Doctor
Name
This field is for validation purposes and should be left unchanged.
×
